Revolutionising Healthcare with Digital Therapeutics: Liva Healthcare’s Partnership with Boots

As healthcare continues to evolve, the role of digital therapeutics (DTx) is becoming increasingly important in managing chronic conditions like obesity, type 2 diabetes, and numerous other cardiovascular diseases. Liva Healthcare is at the forefront of this transformation, delivering innovative, digitally-driven lifestyle management programmes. Our latest partnership with Boots—the UK’s leading health and beauty retailer—marks a significant step in expanding access to these life-changing tools.

A New Era of Personalised Health Support

This partnership allows Boots customers to access Liva Healthcare’s digital-first, personalised health coaching services. Through this collaboration, we are making it easier for people to adopt healthier habits, lose weight, and reduce risk factors for chronic conditions. This service will be available both online and across Boots’ 1,900 UK stores, empowering thousands of people to take control of their health with the support of qualified health coaches.

Shahram Sharif , CEO of Liva Healthcare, said “Digital therapeutics can play a pivotal role in transforming people’s health. By leveraging behavioural science and interactive digital platforms, these tools can support healthier lifestyles, reducing risks for conditions like diabetes and cardiovascular disease. This partnership provides an opportunity to scale these vital programmes, which are already used within the NHS.”

The Impact of Digital Therapeutics

The power of digital therapeutics lies in their ability to offer continuous, personalised care that complements traditional treatment. As highlighted in Liva’s recent white paper, DTx programmes not only enhance patient outcomes but also support healthcare systems by reducing costs and improving efficiency. By integrating digital solutions with behaviour change techniques, Liva Healthcare’s approach has demonstrated measurable success, including significant weight loss and improved HbA1c levels among participants.

In fact, data from Liva’s programmes show that 4 out of 10 people with type 2 diabetes achieve non-diabetic HbA1c levels within six months. Furthermore, 80% of users with prediabetes reduce their HbA1c levels within the same time frame, showing the impact these programmes can have on reversing or managing chronic diseases.

At Liva Healthcare, we are proud of our commitment to improving health outcomes globally, and this partnership with Boots is another stride toward making a real, positive impact on public health.

Click here to read our latest white paper on DTx here: https://www.livahealthcare.com/whitepaper